Serveur d'exploration Tocilizumab - Curation (PubMed)

Index « Auteurs » - entrée « Naoki Matsuoka »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Naoki Kosaka < Naoki Matsuoka < Naoki Oshima  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 4.
Ident.Authors (with country if any)Title
000122 (2020) Jumpei Temmoku [Japon] ; Yuya Fujita [Japon] ; Naoki Matsuoka [Japon] ; Takeshi Urano [Japon] ; Makiko Yashiro Furuya [Japon] ; Tomoyuki Asano [Japon] ; Shuzo Sato [Japon] ; Haruki Matsumoto [Japon] ; Hiroshi Watanabe [Japon] ; Hideko Kozuru [Japon] ; Hiroshi Yatsuhashi [Japon] ; Atsushi Kawakami [Japon] ; Kiyoshi Migita [Japon]Uric acid-mediated inflammasome activation in IL-6 primed innate immune cells is regulated by baricitinib.
000162 (2020) Tomoyuki Asano ; Shuzo Sato ; Jumpei Temmoku ; Yuya Fujita ; Makiko Yashiro Furuya ; Naoki Matsuoka ; Hiroko Kobayashi ; Eiji Suzuki [Japon] ; Hiroshi Watanabe ; Kiyoshi MigitaEffectiveness of Tocilizumab in juvenile patients with refractory Takayasu arteritis: Two case reports.
000534 (2018) Masataka Umeda [Japon] ; Tomohiro Koga [Japon] ; Kunihiro Ichinose [Japon] ; Ayuko Takatani [Japon] ; Takashi Igawa [Japon] ; Toshimasa Shimizu [Japon] ; Shoichi Fukui [Japon] ; Ayako Nishino [Japon] ; Yoshiro Horai [Japon] ; Yasuko Hirai [Japon] ; Shin-Ya Kawashiri [Japon] ; Naoki Iwamoto [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Tomoki Origuchi [Japon] ; Toshiyuki Aramaki [Japon] ; Yukitaka Ueki [Japon] ; Akitomo Okada [Japon] ; Keita Fujikawa [Japon] ; Naoki Matsuoka [Japon] ; Atsushi Kawakami [Japon]Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice.
000E05 (????) Shin-Ya Kawashiri [Japon] ; Ayako Nishino [Japon] ; Takahisa Suzuki [Japon] ; Yoshikazu Nakashima [Japon] ; Yoshiro Horai [Japon] ; Yukitaka Ueki [Japon] ; Toshiyuki Aramaki [Japon] ; Keita Fujikawa [Japon] ; Munetoshi Nakashima [Japon] ; Akitomo Okada [Japon] ; Kiyoshi Migita [Japon] ; Akinari Mizokami [Japon] ; Naoki Matsuoka [Japon] ; Masanobu Mine [Japon] ; Soko Sakito [Japon] ; Naoki Iwamoto [Japon] ; Kunihiro Ichinose [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Tomoki Origuchi [Japon] ; Kiyoshi Aoyagi [Japon] ; Katsumi Eguchi [Japon] ; Atsushi Kawakami [Japon]Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/Author.i -k "Naoki Matsuoka" 
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/Author.i  \
                -Sk "Naoki Matsuoka" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Curation
   |type=    indexItem
   |index=    Author.i
   |clé=    Naoki Matsuoka
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021